Iovel Kutateladze Pharmacochemistry Institute, Tbilisi State Medical University, Tbilisi, Georgia, Institute of Experimental Pharmacology and Toxicology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovak Republic.
Physiol Res. 2019 Nov 22;68(Suppl 1):S75-S85. doi: 10.33549/physiolres.934328.
In this study, two extracts from Fatsia japonica-Fatsiphloginum™ (extract of triterpene glycosides containing 45-50 % of fatsiosides (FS)) and purified triterpene-rich extract of saponins with code name PS-551 (PS) were administered in combination with methotrexate (MTX) and in monotherapy to rats suffering adjuvant arthritis (AA). The anti-inflammatory activities of extracts were evaluated as monotherapies in comparison with untreated AA. PS administered in higher dose showed on day 28 effective decrease of hind paw volume (HPV), decreased activity of gamma-glutamyl transferase (GGT) in joints, and also interleukin-17A was decreased significantly on day 14. The higher dose of PS was more effective than both doses of FS. Further, we evaluated the higher doses of PS and FS in combination with MTX. PS improved the effect of MTX in combination more effective than FS (HPV, body weight and activity of GGT in joint). However, FS was more effective in reducing the level of IL-17A on day 14 and activity of GGT in spleen than PS. In conclusion, our study showed that generally FS has higher anti-arthritic activity comparing to PS. Thus, the novel combination of Fatsiphloginum™ and methotrexate could be interesting for future clinical studies in patients suffering auto-immune diseases.
在这项研究中,两种从八角金盘 - 八角金盘苷(含有 45-50%的八角糖苷(FS)的三萜糖苷提取物)和纯化的皂甙三萜类提取物 PS-551(PS)中提取的物质与甲氨蝶呤(MTX)联合给药,并在单独用药的情况下用于治疗佐剂性关节炎(AA)大鼠。提取物的抗炎活性在单独用药时与未经治疗的 AA 进行了比较。在第 28 天,高剂量 PS 给药显示出有效的后爪体积(HPV)减少,关节中γ-谷氨酰转移酶(GGT)活性降低,并且白细胞介素-17A 在第 14 天显著降低。高剂量 PS 比两种剂量的 FS 都更有效。此外,我们评估了 PS 和 FS 的高剂量联合使用与 MTX 的联合作用。PS 改善了 MTX 的联合效果,比 FS 更有效(HPV、体重和关节中 GGT 的活性)。然而,FS 在第 14 天降低 IL-17A 水平和脾脏中 GGT 活性方面比 PS 更有效。总之,我们的研究表明,一般来说,FS 比 PS 具有更高的抗关节炎活性。因此,八角金盘苷和甲氨蝶呤的新型组合可能对未来治疗自身免疫性疾病患者的临床研究具有重要意义。